SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

06 يناير 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

18 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

14 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

07 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

29 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

16 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

11 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

01 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أكتوبر 2024 00:05:00 بحسب Nasdaq GlobeNewswire

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

12 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

04 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

14 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

01 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 

10 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

06 يونيو 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

16 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

07 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

06 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire